Thomas Jordan, MD

Research Update

Do Psychosocial Interventions Improve Quality of Life in Advanced Dementia?

July 11, 2023

Thomas Jordan, MD

Thomas Jordan, MD. Dr. Jordan has no financial relationships with companies related to this material.

A systematic review finds only aromatherapy and reminiscence therapy improve quality of life in advanced dementia.

RESEARCH UPDATE

Vyvanse for Sluggish Cognitive Tempo in ADHD

August 1, 2022

Thomas Jordan, MD

Thomas Jordan, MD. Dr. Jordan, author for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

This study won’t tell us if “sluggish cognitive tempo” is a valid disorder, but it does show how Vyvanse works in this controversial subtype of ADHD.
Research Update

Annual Flu Vaccines

July 1, 2022

Thomas Jordan, MD

Thomas Jordan, MD. Dr. Jordan, author of this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Although there is an association between influenza vaccinations and a lower dementia risk, association is not causation.

Psychiatry Practice Boosters, Third Edition (2021)

PDF Access and CME Post-Test

February 28, 2021

Thomas Jordan, MD

Thomas Jordan, MD, MPH

Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This page has links and instructions for downloading your PDF and eBook copies of Psychiatry Practice Boosters 2021 and completing the 10 CME Post-Test.

Gabapentin Enacarbil XR Efficacy Less Than Expected for AUD

August 1, 2019

Thomas Jordan, MD

Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This 2019 randomized, double-blind, placebo- controlled trial study casts doubt on using gabapentin enacarbil extended-release (GE-XR) (Horizant), an extended-release version of gabapentin, for treatment in patients with alcohol use disorder

Can Buprenorphine Improve PTSD Symptoms?

August 1, 2019

Thomas Jordan, MD

Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

This 2019 retrospective study examines the potential benefits of using buprenorphine/naloxone to treat co-occurring PTSD and opioid use disorder.

The FDA Campaigns Against Flavored Tobacco Products

February 27, 2019

Thomas Jordan, MD and Talia Puzantian, Pharm.D.

Thomas Jordan, MD Talia Puzantian, Pharm.D. Drs. Jordan and Puzantian have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Electronic cigarette use, or vaping, is becoming increasingly common. Companies manufacturing e-cigarettes advertise them as alternatives to conventional cigarettes and even a pathway to smoking cessation. However, the popularity of vaping has sky-rocketed in high schools across the country with adolescents becoming addicted to nicotine daily.

Psychiatry Practice Boosters, Second Edition (2018)

PDF Access and CME Post-Test

September 30, 2018

Thomas Jordan, MD

Teaches you the key points of 42 of the most clinically relevant studies in psychiatry published between 2016 to 2018.

Can Computerized Interventions Reduce Cannabis Use?

July 1, 2018

Thomas Jordan, MD

Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

As medical and recreational marijuana become legalized in more states, more emphasis is being placed on treatment of those with cannabis use disorders. But with our clinics already at capacity, how can we find the most efficient way of providing therapy?

Simvastatin as Adjunctive Therapy for Irritability in Autism

June 21, 2018

Thomas Jordan, MD

Thomas Jordan, MD Dr. Jordan has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Disorders of lipid metabolism—specifically inefficient metabolism of lipids—have been implicated as part of the metabolic complexity in children with autism spectrum disorder. Research points to the neuroprotective effects of simvastatin over other statins, due to its greater ability to cross the blood-brain barrier. But does that neuroprotection translate to differences in behavior?